Search company, investor...


Founded Year



Acquired | Acquired

Total Raised




About TransVascular

TransVascular was formed to develop percutaneous approaches for the revascularization of occluded vessels. The company was acquired by Medtronic.

Headquarters Location

1505-D Adams Drive 1505 D Adams Drive

Menlo Park, California, 94025,

United States


Missing: TransVascular's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: TransVascular's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest TransVascular News

Caisson Interventional Completes First in Human Implants of Its Transvascular Mitral Valve Replacement

Sep 16, 2016

NYU Langone Medical Center Implants First Patients with Groundbreaking New Investigational Device September 16, 2016 08:18 ET | Source: Caisson Interventional MAPLE GROVE, Minn., Sept. 16, 2016 (GLOBE NEWSWIRE) -- Caisson Interventional, LLC (“Caisson” or the “Company”) announces the first successful human implants of its fully percutaneous, transvascular mitral valve implant designed as a functional replacement in a diseased, damaged, or malfunctioning mitral valve. and his team from the Heart Valve Center at NYU Langone successfully implanted three patients with the Caisson Transcatheter Mitral Valve System. These are the first patients enrolled in the PRELUDE Study (Percutaneous Mitral Valve Replacement EvaLuation Utilizing IDE Early Feasibility Study). The study is designed to provide initial data on the safety and performance of the Caisson TMVR System. The U.S. Food and Drug Administration (FDA) approved the Investigational Device Exemption (IDE) for the PRELUDE study under the Early Feasibility Study program for up to 20 patients in 5 centers. The Company also reports one patient was successfully implanted in July under the direction of Eric Cohen, M.D. and Gideon Cohen, M.D. at the Schulich Heart Centre at Sunnybrook Health Sciences Centre (Toronto) under the Health Canada Special Access Programme. The physicians involved stated the patients responded very well to the implant with excellent valve function. They also commented the delivery system performed as designed and facilitated proper placement of the implant with precise control at each step of the procedure. Dr. Williams, NYU Langone’s chief of Adult Cardiac Surgery, and director of Interventional Cardiology and Structural Heart commented, “NYU Langone is a recognized world leader in cardiac care and we are dedicated to bringing the most advanced minimally-invasive technologies to our patients. We are proud to be the first medical center in the world to successfully implant three high risk patients with Caisson’s cutting-edge new technology to treat their severe symptomatic mitral regurgitation. Thanks to NYU Langone’s focus on innovation in the field, and the FDA’s dedication to the Early Feasibility Study (EFS) Program, we have the opportunity to be involved with this first-in-class technology at the earliest stage of clinical evaluation.” The Caisson implant consists of two components; an Anchor constructed of a Nitinol frame and a pericardial tissue Valve attached to a Nitinol frame. The implant is fully repositionable and retrievable and only released after the function of the implant is fully assessed. The entire procedure is completed through a single percutaneous femoral venous access utilizing a trans-septal approach to the native mitral valve. Caisson Interventional CEO C.J. Schweich Jr., M.D. said, “We are thankful to the NYU Langone and Sunnybrook teams for their dedication to outstanding patient care and participation in this groundbreaking clinical experience. These initial implants mark a significant milestone for Caisson’s technology in understanding its potential to benefit a significant number of patients with severe mitral regurgitation and limited therapeutic options.”                                                                        About the company: Caisson Interventional, LLC. is a privately held clinical-stage medical device company located in the Minneapolis area focused on the design, development, and clinical evaluation of a novel percutaneous mitral valve replacement system. The Caisson Mitral Valve Replacement System is approved for investigational use in the United States and therefore limited by Federal (or United States) law to investigational use only. CONTACT:Caisson Interventional, LLCC.J. Schweich, Jr., M.D.Chief Executive Related Articles

TransVascular Frequently Asked Questions (FAQ)

  • When was TransVascular founded?

    TransVascular was founded in 1996.

  • Where is TransVascular's headquarters?

    TransVascular's headquarters is located at 1505-D Adams Drive, Menlo Park.

  • What is TransVascular's latest funding round?

    TransVascular's latest funding round is Acquired.

  • How much did TransVascular raise?

    TransVascular raised a total of $46.95M.

  • Who are the investors of TransVascular?

    Investors of TransVascular include Medtronic, Bessemer Venture Partners, Three Arch Partners, Johnson & Johnson, JOMED and 4 more.

  • Who are TransVascular's competitors?

    Competitors of TransVascular include Inspire Medical Systems, Ocular Therapeutix, NeoVista, Helicon Therapeutics, Orthovita and 11 more.

Compare TransVascular to Competitors

Precision Parts International

PPI was formed from the merger of three companies (MPI International, Skill Tool & Die, and Precision Gear) to manufacture complex, high-precision metal components for the automotive, defense, medical device and construction industries.

Neuros Medical Logo
Neuros Medical

Neuros Medical focuses on the development of proprietary therapies for the unmet needs of patients worldwide. The company's Altius system treats chronic post-amputation pain (Phantom Limb Pain and Residual Limb Pain). Altius incorporates the Company’s patented platform technology, On-Demand Bioelectric Nerve Block. Patients initiate a 30-minute Altius treatment session as needed for targeted pain relief. Neuros Medical was founded in 2008 and is based in Willoughby, Ohio.

CeQur Logo

CeQur is developing and commercializing advanced yet simple-to-use insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease. The Company's fully optimized device, PaQ, is a three-day, wearable device that provides freedom from multiple daily insulin injections.


Neuromonics is an Australian company that has developed an FDA approved device for treatment of tinnitus over a six month process with 2 hours of use per day.

Aethlon Medical Logo
Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier - medical device that aims to treat infectious disease.

Mercator MedSystems

Mercator MedSystems has developed a broad-based therapeutic platform that allows clinicians to accurately and efficiently deliver drugs and biologics such as stem cells to tissues deep in the body, treating the root cause of significant medical conditions. The company utilizes its family of Micro-Infusion Catheters for targeted treatments via the vascular system, including peripheral artery disease (PAD) and resistant hypertension (HTN); and via the bronchial tree, including malignant airway obstruction secondary to lung cancer. The company's 510(k)-cleared and CE-Marked Cricket and Bullfrog Micro-Infusion Catheters are vascular-access systems that are able to inject drugs, genes, and cells safely through vessel walls into deep tissues without major surgery.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.